Different Effects of Tacrolimus on Innate and Adaptive Immune Cells in the Allograft Transplantation

Scandinavian Journal of Immunology

Volumn 83, Issue 2, 2016, Pages 119-127

  Shao, K ^a,b   Lu, Y ^b,c   Wang, J ^b,c   Chen, X ^b,c   Zhang, Z ^b,c   Wang, X ^a,b,d   Yang, H ^b   Liu, G ^b,c  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c Beijing Normal University   (China)

^d Fudan University ^*  (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; TACROLIMUS; CALCINEURIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ADAPTIVE IMMUNITY; ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVATION; CELL ACTIVITY; CELL COUNT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFECT; DRUG TARGETING; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN TRANSPLANTATION; T LYMPHOCYTE; ALLOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; C57BL MOUSE; DRUG EFFECTS; ESCHERICHIA COLI; FEMALE; IMMUNOLOGY; MALE; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; TRANSPLANTATION TOLERANCE;

ADAPTIVE IMMUNITY; ALLOGRAFTS; ANIMALS; CALCINEURIN INHIBITORS; ESCHERICHIA COLI; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNITY, INNATE; IMMUNOSUPPRESSIVE AGENTS; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MODELS, IMMUNOLOGICAL; NEUTROPHILS; PHAGOCYTOSIS; SKIN TRANSPLANTATION; T-LYMPHOCYTES; TACROLIMUS; TRANSPLANTATION TOLERANCE;

EID: 84955569856     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12398     Document Type: Article

References (52)

1. Martina MR, Tenori E, Bizzarri M, Menichetti S, Caminati G, Procacci P. The precise chemical-physical nature of the pharmacore in FK506 binding protein inhibition: ElteX, a New class of nanomolar FKBP12 ligands. J Med Chem 2013;56:1041-51.
2. Backman L, Nicar M, Levy M et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. Transplantation 1994;57:519-25.
3. Jindal RM, Popescu I, Emre S et al. Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506. Transplantation 1994;57:1395-8.
4. Kadry Z, Bronsther O, Fung JJ. Kaposi's sarcoma in liver transplant recipients on FK506. Transplantation 1998;65:1140-8.
5. Reyes J, Gayowski T, Fung J, Todo S, Alessiani M, Starzl TE. Expressive dysphasia possibly related to FK506 in two liver transplant recipients. Transplantation 1990;50:1043-5.
6. Sokol DK, Molleston JP, Filo RS, Van Valer J, Edwards-Brown M. Tacrolimus (FK506)-induced mutism after liver transplant. Pediatr Neurol 2003;28:156-8.
7. Klein A. Tacrolimus rescue in liver transplant patients with refractory rejection or intolerance or malabsorption of cyclosporine. The US Multicenter FK506 Liver Study Group. Liver Transpl Surg 1999;5:502-8.
8. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992;357:695-7.
9. Kelly P, Kahan BD. Review: metabolism of immunosuppressant drugs. Curr Drug Metab 2002;3:275-87.
10. Wu X, Nguyen BC, Dziunycz P et al. Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature 2010;465:368-2.
11. Richardson D, Jones CH, Newstead CG, Will EJ, Lodge JP. The successful conversion to Tacrolimus (FK506) of a renal transplant recipient with cyclosporin-induced haemolytic-uraemic syndrome. Nephrol Dial Transpl 1996;11:2498-500.
12. Abou-Jaoude MM, Najm R, Shaheen J et al. Tacrolimus (FK506) versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney transplant recipients. Transpl Proc 2005;37:3025-8.
13. Hayashi Y, Shumsky JS, Connors T et al. Immunosuppression with either cyclosporine a or FK506 supports survival of transplanted fibroblasts and promotes growth of host axons into the transplant after spinal cord injury. J Neurotrauma 2005;22:1267-81.
14. Abou-Jaoude MM, Irani-Hakime N, Ghantous I, Najm R, Afif C, Almawi WY. Cyclosporine microemulsion (Neoral) versus tacrolimus (FK506) as maintenance therapy in kidney transplant patients. Transpl Proc 2003;35:2748-9.
15. Maes BD, Lemahieu W, Kuypers D et al. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. Am J Transpl 2002;2:989-92.
16. Selzner N, Durand F, Bernuau J et al. Conversion from cyclosporine to FK506 in adult liver transplant recipients: a combined North American and European experience. Transplantation 2001;72:1061-5.
17. Vela CG, Cristol JP, Descomps B, Mourad G. Prospective study of lipid disorders in FK506-versus cyclosporine-treated renal transplant patients. Transpl Proc 2000;32:398-405.
18. Arthur JM, Shamim S. Interaction of cyclosporine and FK506 with diuretics in transplant patients. Kidney Int 2000;58:325-30.
19. Periyasamy S, Warrier M, Tillekeratne MP, Shou W, Sanchez ER. The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms. Endocrinology 2007;148:4716-26.
20. Sommerer C, Zeier M, Meuer S, Giese T. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. Transplantation 2010;89:1417-23.
21. Wu Z, Meng Q, Xia Y, Zhang F, You W. A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients. J Biomed Res 2013;27:305-9.
22. Rosenberg AS, Mizuochi T, Singer A. Evidence for involvement of dual-function T cells in rejection of MHC class I disparate skin grafts. Assessment of MHC class I alloantigens as in vivo helper determinants. J Exp Med 1988;168:33-45.
23. Rosenberg AS, Munitz TI, Maniero TG, Singer A. Cellular basis of skin allograft rejection across a class I major histocompatibility barrier in mice depleted of CD8+ T cells in vivo. J Exp Med 1991;173:1463-71.
24. Mayumi H, Nomoto K, Good RA. A surgical technique for experimental free skin grafting in mice. Jpn J Surg 1988;18:548-57.
25. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973;16:343-50.
26. Siemionow M, Demir Y, Mukherjee A, Klimczak A. Development and maintenance of donor-specific chimerism in semi-allogenic and fully major histocompatibility complex mismatched facial allograft transplants. Transplantation 2005;79:558-67.
27. Sun B, Hu X, Liu G et al. Phosphatase wip1 negatively regulates neutrophil migration and inflammation. J Immunol 2014;192:1184-95.
28. Liu G, Bi Y, Xue L et al. Dendritic cell SIRT1-HIF1alpha axis programs the differentiation of CD4+ T cells through IL-12 and TGF-beta1. Proc Natl Acad Sci USA 2015;112:E957-65.
29. Schumann J, Prockl J, Kiemer AK, Vollmar AM, Bang R, Tiegs G. Silibinin protects mice from T cell-dependent liver injury. J Hepatol 2003;39:333-40.
30. Cripps JG, Wang J, Maria A, Blumenthal I, Gorham JD. Type 1 T helper cells induce the accumulation of myeloid-derived suppressor cells in the inflamed Tgfb1 knockout mouse liver. Hepatology 2010;52:1350-9.
31. Liu G, Burns S, Huang G et al. The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. Nat Immunol 2009;10:769-77.
32. Bi Y, Zhou J, Yang H et al. IL-17A produced by neutrophils protects against pneumonic plague through orchestrating IFN-gamma-activated macrophage programming. J Immunol 2014;192:704-13.
33. Curtis JJ, Kaplan B. Transplant immunosuppressive drug trials on trial. Am J Transpl 2004;4:671-2.
34. Tange S, Scherer MN, Graeb C et al. The antineoplastic drug Paclitaxel has immunosuppressive properties that can effectively promote allograft survival in a rat heart transplant model. Transplantation 2002;73:216-23.
35. Marfo K, Greenstein S. Antiretroviral and immunosuppressive drug-drug interactions in human immunodeficiency virus-infected liver and kidney transplant recipients. Transpl Proc 2009;41:3796-9.
36. Nesci DA, Favale C, Foco M, Castagneto M, Nanni G. Psychodynamic evaluation of kidney transplant patients enrolled in a new immunosuppressive drug trial. Transpl Proc 2001;33:1907-8.
37. Guttmann RD. Post-transplant immunosuppressive drug infusions and donor pretreatment. Transplantation 1980;29:176-83.
38. Sampaio MS, Poommipanit N, Kuo HT et al. Induction therapy in pediatric kidney transplant recipients discharged with a triple drug immunosuppressive regimen. Pediatr Transplant 2010;14:770-8.
39. Tanriover B, Stone PW, Mohan S, Cohen DJ, Gaston RS. Future of Medicare immunosuppressive drug coverage for kidney transplant recipients in the United States. Clin J Am Soc Nephrol 2013;8:1258-66.
40. Kuypers DR. Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome. Transpl Int 2005;18:140-50.
41. Muthukkumar S, Ramesh TM, Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation 1995;60:264-70.
42. Marinkovic G, Hibender S, Hoogenboezem M et al. Immunosuppressive drug azathioprine reduces aneurysm progression through inhibition of Rac1 and c-Jun-terminal-N-kinase in endothelial cells. Arterioscler Thromb Vasc Biol 2013;33:2380-8.
43. Qu Y, Zhang B, Zhao L et al. The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice. Transpl Immunol 2007;17:153-61.
44. Zeiser R, Negrin RS. Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle 2008;7:458-62.
45. Gonzalez F. Empirical or unconscious reduction of the secondary immunosuppressive drug concomitantly with intended calcineurin inhibitor reduced exposure to improve kidney graft function can be followed by antibody mediated rejections. Clin Transplant 2015;29:277-8.
46. Wang X, Bi Y, Xue L et al. The calcineurin-NFAT axis controls allograft immunity in myeloid-derived suppressor cells through reprogramming T cell differentiation. Mol Cell Biol 2015;35:598-609.
47. Ruhlmann A, Nordheim A. Effects of the immunosuppressive drugs CsA and FK506 on intracellular signalling and gene regulation. Immunobiology 1997;198:192-206.
48. Yu Z, Zhou X, Yu S, Xie H, Zheng S. IL-15 is decreased upon CsA and FK506 treatment of acute rejection following heart transplantation in mice. Mol Med Rep 2015;11:37-42.
49. Yard BA, Pancham RR, Paape ME, Daha MR, van Es LA, van der Woude FJ. CsA, FK506, corticosteroids and rapamycin inhibit TNF alpha production by cultured PTEC. Kidney Int 1993;44:352-8.
50. Jeanmart H, Perrault LP, Carrier M, Cartier R, Nickner C. Comparative study of CSA and FK506 versus newer immunosuppressive drugs MMF and rapamycin on coronary endothelial function in vitro. J Heart Lung Transpl 2001;20:235-43.
51. Rinschen MM, Klokkers J, Pavenstadt H, Neugebauer U, Schlatter E, Edemir B. Different effects of CsA and FK506 on aquaporin-2 abundance in rat primary cultured collecting duct cells. Pflugers Arch 2011;462:611-22.
52. Cho CS, Elkahwaji J, Chang Z, Scheunemann TL, Manthei ER, Hamawy MM. Modulation of the electrophoretic mobility of the linker for activation of T cells (LAT) by the calcineurin inhibitors CsA and FK506: LAT is a potential substrate for PKC and calcineurin signaling pathways. Cell Signal 2003;15:85-93.